AstraZeneca, the British-Swedish pharmaceutical company, announced positive results during the last stages of trials of a new drug for the treatment of liver cancer called “Imfenzi” by using it with monoclonal antibodies, in a promising development for the treatment of this incurable disease.
And the Bloomberg News Agency quoted the company as saying that adding a single dose of monoclonal antibodies to Imfenzi “had a statistically and clinically significant effect on the benefit of this drug in general in terms of preserving the lives of patients,” compared to the drug “Sorafenib” provided by the company. competition, which makes Imfinzi the “first-line” treatment for patients with hepatocellular carcinomas, who have limited treatment options.
Bloomberg quoted Ghassan Abu Alfa, one of the main researchers participating in the experiment, as saying that the drug “helps to raise the efficiency of the body’s immune system in the face of cancer cells, with the aim of extending the patient’s life to the maximum, with the least possible side effects.”
It is noteworthy that liver cancer is the third most common cause of death among cancer types, and the sixth most common cancer in the world, as 900,000 people are diagnosed with this disease annually, and seven percent of liver cancer patients remain alive after five years of treatment. their illness.